IL145282A0 - Compositions and methods for treatment of staphylococcal infection - Google Patents

Compositions and methods for treatment of staphylococcal infection

Info

Publication number
IL145282A0
IL145282A0 IL14528200A IL14528200A IL145282A0 IL 145282 A0 IL145282 A0 IL 145282A0 IL 14528200 A IL14528200 A IL 14528200A IL 14528200 A IL14528200 A IL 14528200A IL 145282 A0 IL145282 A0 IL 145282A0
Authority
IL
Israel
Prior art keywords
compositions
treatment
methods
staphylococcal infection
staphylococcal
Prior art date
Application number
IL14528200A
Other languages
English (en)
Original Assignee
Nutrition 21
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 filed Critical Nutrition 21
Publication of IL145282A0 publication Critical patent/IL145282A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14528200A 1999-03-05 2000-03-03 Compositions and methods for treatment of staphylococcal infection IL145282A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/263,776 US6569830B1 (en) 1999-03-05 1999-03-05 Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
PCT/US2000/005464 WO2000051588A1 (en) 1999-03-05 2000-03-03 Compositions and methods for treatment of staphylococcal infection

Publications (1)

Publication Number Publication Date
IL145282A0 true IL145282A0 (en) 2002-06-30

Family

ID=23003182

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14528200A IL145282A0 (en) 1999-03-05 2000-03-03 Compositions and methods for treatment of staphylococcal infection

Country Status (14)

Country Link
US (4) US6569830B1 (de)
EP (1) EP1181011A4 (de)
JP (1) JP2002538108A (de)
KR (1) KR20020010893A (de)
CN (1) CN1353602A (de)
AR (1) AR022791A1 (de)
AU (1) AU780864B2 (de)
BR (1) BR0008779A (de)
CA (1) CA2362487A1 (de)
IL (1) IL145282A0 (de)
NO (1) NO20014314L (de)
PL (1) PL364875A1 (de)
WO (1) WO2000051588A1 (de)
ZA (1) ZA200108215B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
EP1567868A4 (de) * 2002-12-02 2008-02-06 Biosynexus Inc ZELLWAND-TEICHONSûURE ALS ZIEL F RANTI-STAPHYLOCOCCUS-THERAPIEN UND -IMPFSTOFFE
BRPI0506535A (pt) * 2004-01-23 2007-02-27 Nereus Pharmaceuticals Inc pirroles bis-indole úteis como agentes anti-microbiais
US7522663B2 (en) * 2005-03-10 2009-04-21 Stmicroelectronics, Inc. Burst error limiting feedback equalizer system and method for multidimensional modulation systems
US20100080790A1 (en) * 2005-07-13 2010-04-01 University Of South Carolina Sterilization using high-pressure carbon dioxide
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080015835A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20080015787A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009152298A1 (en) * 2008-06-13 2009-12-17 Zeus Scientific, Inc. Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase
CN102348718B (zh) 2009-01-14 2015-06-03 诺瓦克塔生物系统有限公司 去氧阿肽加定衍生物
EP2393829A1 (de) 2009-02-04 2011-12-14 Novacta Biosystems Limited Actagardinderivate
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
WO2014071198A1 (en) * 2012-11-01 2014-05-08 The University Of Chicago Antibiotic methods and compositions for bacteria infections
CA2934670A1 (en) * 2013-12-28 2015-07-02 StaphRx, LLC Ultra-low dose lysostaphin for treating mrsa
US10358636B2 (en) 2014-05-14 2019-07-23 Stealth Biologics, Llc Deimmunized lysostaphin and methods of use
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278378A (en) 1962-04-19 1966-10-11 Schindler Charles Alvin Staphylococcus-derived antibiotic
US3398056A (en) 1964-07-10 1968-08-20 Mead Johnson & Co Process for producing lysostaphin by fermentation
US3594284A (en) 1968-06-04 1971-07-20 Mead Johnson & Co Lysostaphin fermentation with accelerated time cycle
US4931390A (en) 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US5304540A (en) * 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
AU623864B2 (en) 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections
JPH0645553B2 (ja) * 1988-09-19 1994-06-15 アプライド マイクロバイオロジィ，インコーポレイテッド 乳房炎およびその他のブドウ球菌感染症の治療法並びに同治療用組成物
US5466685A (en) * 1993-05-13 1995-11-14 Johnson & Johnson Inhibition of expression of beta-lactamase using esters of fatty acid alcohols
EP1001804B1 (de) * 1997-07-23 2006-02-01 AMBI Inc. Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
US6028051A (en) 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

Also Published As

Publication number Publication date
AU3249000A (en) 2000-09-21
AU780864B2 (en) 2005-04-21
AR022791A1 (es) 2002-09-04
US8198231B2 (en) 2012-06-12
US20060246055A1 (en) 2006-11-02
WO2000051588A1 (en) 2000-09-08
EP1181011A4 (de) 2003-05-21
ZA200108215B (en) 2006-03-29
KR20020010893A (ko) 2002-02-06
PL364875A1 (en) 2004-12-27
US6569830B1 (en) 2003-05-27
US7078377B1 (en) 2006-07-18
US20030199432A1 (en) 2003-10-23
NO20014314D0 (no) 2001-09-05
CN1353602A (zh) 2002-06-12
NO20014314L (no) 2001-10-11
BR0008779A (pt) 2002-10-15
EP1181011A1 (de) 2002-02-27
US7122514B2 (en) 2006-10-17
JP2002538108A (ja) 2002-11-12
CA2362487A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
IL145282A0 (en) Compositions and methods for treatment of staphylococcal infection
AU2001280702A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
PL355977A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0400477A3 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
EP1227821A4 (de) Therapeutische zusammensetzungen und verfahren zur verwendung davon
EP1461024A4 (de) Behandlung von wunden und eingesetzte zusammensetzungen
HUP0201117A2 (en) Attenuated microorganisms for the treatment of infection
GB0127618D0 (en) "Composition and method for treatment of wounds"
AU2420101A (en) Method and composition for the treatment of pain
IL151403A0 (en) Compositions and methods for treatment of epilepsy
HK1046913A1 (zh) 為治療傳染病的被縮小微生物
HUP0200466A3 (en) Lipoglycan compositions and methods of treating parasitic infections
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2001292943A1 (en) Prevention and treatment of streptococcal and staphylococcal infection
AU2001282277A1 (en) Treatment of mycobacterial infection
HUP0300043A3 (en) Method and composition for the treatment of pain
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU1621501A (en) Methods and compositions for treatment of disease
GB0026748D0 (en) Composition and method for treatment of wounds
AU2001247546A1 (en) Method and composition for treatment and prevention of alopecia
AUPQ136699A0 (en) Method for treatment of cancer and compositions for use therein
GB9917181D0 (en) Methods of treatment
GB9901310D0 (en) Methods of treatment